LOGIN  |  REGISTER
Chimerix

Caris Life Sciences (NASDAQ: CAI) Stock Quote

Last Trade: US$31.26 -1.69 -5.13
Volume: 395,743
5-Day Change: 3.07%
YTD Change: 14.72%
Market Cap: US$8.790B

Latest News From Caris Life Sciences

IRVING, Texas , Aug. 15, 2025 /PRNewswire/ -- Caris Life Sciences ® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, has published a study in Oncotarget validating the analytical and clinical performance of MI Cancer Seek ® . This FDA-approved assay is used as a companion diagnostic (CDx) to identify cancer patients who may benefit from targeted therapies. It... Read More
IRVING, Texas , Aug. 13, 2025 /PRNewswire/ -- Caris Life Sciences ® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, published results in Breast Cancer Research comparing the effectiveness and optimal sequencing of two antibody-drug conjugates, trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG), in HER2-negative breast cancer patients. The study found... Read More
IRVING, Texas , July 23, 2025 /PRNewswire/ -- Caris Life Sciences ® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced it will report second quarter 2025 financial results on Tuesday, August 12, 2025 . Caris Life Sciences will host a conference call and live webcast at 3:30 p.m. CT ( 4:30 p.m. ET ) to discuss the financial results. Conference Call... Read More
Validation was shared via a Letter to the Editor in the New England Journal of Medicine IRVING, Texas , July 22, 2025 /PRNewswire/ -- Caris Life Sciences ® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, published original data in the New England Journal of Medicine independently validating recent findings on tumor-infiltrating clonal hematopoiesis (TI-CH), and... Read More
Scientific Reports study validates the first multifunctional, AI-enabled blood-based assay to offer diagnostic, prognostic and predictive utility in a single assay. IRVING, Texas , July 8, 2025 /PRNewswire/ -- Caris Life Sciences ® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, announced a landmark study published in Scientific Reports, a Nature journal,... Read More
Astria Therapeutics